Skip to main content
Premium Trial:

Request an Annual Quote

Driven by Clinical Business, Cepheid's Q3 Revenues Rise 24 Percent

NEW YORK (GenomeWeb News) – Cepheid’s third-quarter revenues grew 24 percent, and the firm posted a 36 percent rise in net loss in the three-month period ended Sept. 30.
The Sunnyvale, Calif.-based molecular diagnostics firm brought in revenues of $44.9 million for the quarter compared to $36.3 million in the comparable quarter of 2007.
System product sales decreased 12 percent to $14 million from $15.9 million, while reagent and disposables sales jumped by 57 percent to $28.4 million from $18.1 million.
Total clinical sales rose 43 percent to $29.6 million from $20.7 million, while industrial sales declined about 5 percent to $4.2 million from $4.4 million and biothreat sales dipped about 3 percent to $8.6 million from $8.9 million.
Cepheid CEO John Bishop said in a statement that the third-quarter revenue bump came from “very strong North American system placements” and increased sales of MRSA tests.
Cepheid’s net loss increased to $6.5 million, or $.11 per share, from $4.7 million, or $.09 per share, in the third quarter of 2007.
The company’s R&D spending increased 38 percent to $11.6 million from $8.4 million, while its SG&A costs grew 24 percent to $13.4 million from $10.8 million.
Cepheid finished the quarter with $24.4 million in cash and cash equivalents.
The company said it expects total revenue for 2008 to be in the range of $174 million to $176 million, and the company foresees a net loss for the year between $22.5 million and $23.5 million.
In early Wednesday trade on the Nasdaq, Cepheid’s shares were up nearly 13 percent at $10.43.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.